DeepMed Research

HACKENSACK MERIDIAN HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2016-01-01

Employees: -

Market Cap: -

Website: https://www.hackensackmeridianhealth.org/

Clinical Trials

NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Phase 1

Completed

Conditions: Glioblastoma, Adult

Interventions: Device: NovoTTF-200A
Drug: Temozolomide
Radiation: 3D conformal or intensity modulated radiation therapy (IMRT)

First Posted Date: 2017-07-28

Last Posted Date: 2024-11-18

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 12

Registration Number: NCT03232424

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Refractory Diffuse Large B-Cell Lymphoma
Relapsed Diffuse Large B-Cell Lymphoma

Interventions: Drug: 400mg ABT-199
Drug: Ibrutinib
Drug: Rituximab
Drug: 800mg ABT-199

First Posted Date: 2017-05-02

Last Posted Date: 2022-10-10

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 10

Registration Number: NCT03136497

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

HUMC 1612: Optune NovoTTF-200A System

Phase 1

Active, not recruiting

Conditions: High Grade Glioma
Ependymoma

Interventions: Device: Optune NovoTTF-200A System

First Posted Date: 2017-04-25

Last Posted Date: 2024-11-22

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 7

Registration Number: NCT03128047

Locations: 🇺🇸
Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Arnold Palmer Hospital for Children, Orlando, Florida, United States

Accurate Display of Postpartum Hemorrhage Using Triton (ADOPT)

Completed

Conditions: Post-partum Hemorrhage (PPH)

First Posted Date: 2016-12-05

Last Posted Date: 2020-02-11

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 300

Registration Number: NCT02981758

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Pembrolizumab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2016-09-20

Last Posted Date: 2023-08-22

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 12

Registration Number: NCT02906332

Locations: 🇺🇸
John Theurer Cancer Center-Hackensack Meridian Health, Hackensack, New Jersey, United States

Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia and Myelodysplastic Syndrome

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2016-07-27

Last Posted Date: 2024-11-18

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 8

Registration Number: NCT02846376

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

Trial of Exercise to Reduce Cancer Related Fatigue in Breast Cancer

Not Applicable

Active, not recruiting

Conditions: Cancer Related Fatigue

Interventions: Other: Moderate Exercise

First Posted Date: 2016-07-27

Last Posted Date: 2022-09-07

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 24

Registration Number: NCT02846389

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence

Phase 1

Terminated

Conditions: Multiple Myeloma
Lymphoma

Interventions: Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2016-02-12

Last Posted Date: 2024-06-17

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 35

Registration Number: NCT02681302

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
Hackensack University medical Center, Hackensack, New Jersey, United States

A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus Type 1

Interventions: Biological: Stem Cell Educator Therapy

First Posted Date: 2015-12-08

Last Posted Date: 2024-10-10

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 13

Registration Number: NCT02624804

Locations: 🇺🇸
Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey, United States

Start Time Optimization of Biologics in Polyarticular JIA

Completed

Conditions: Polyarticular Juvenile Rheumatoid Arthritis
Arthritis, Juvenile Idiopathic

First Posted Date: 2015-10-30

Last Posted Date: 2021-02-05

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 400

Registration Number: NCT02593006

Locations: 🇺🇸
Emory Children's Center, Atlanta, Georgia, United States
🇺🇸
University of Vermont Medical Center, Burlington, Vermont, United States
🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada

and more 52 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy